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BACKGROUND: Secreted protein acidic and rich in cysteine (SPARC) is a multi-faceted protein-modulating cell–cell and cell–matrix
interactions. In cancer, SPARC can be not only associated with a highly aggressive phenotype, but also acts as a tumour suppressor.
The aim of this study was to characterise the function of SPARC and its modulation by fibroblast growth factor receptor (FGFR) 1
isoforms in pancreatic ductal adenocarcinoma (PDAC).
METHODS AND RESULTS: Exogenous SPARC inhibited growth, movement, and migration. ShRNA inhibition of endogenous SPARC in
ASPC-1 and PANC-1 cells resulted in increased anchorage-dependent and -independent growth, transwell migration, and xenograft
growth as well as increased mitogenic efficacy of fibroblast growth factor (FGF) 1 and FGF2. Endogenous SPARC expression in
PANC-1 cells was increased in FGFR1-IIIb over-expressing cells, but decreased in FGFR1-IIIc over-expressing cells. The up-regulation
of endogenous SPARC was abrogated by the p38-mitogen-activated protein kinase inhibitor SB203580. SPARC was detectable
in conditioned medium of pancreatic stellate cells (PSCs), but not PDAC cells. Conditioned medium of PDAC cells reduced
endogenous SPARC expression of PSCs.
CONCLUSION: Endogenous SPARC inhibits the malignant phenotype of PDAC cells and may, therefore, act as a tumour suppressor
in PDAC. Endogenous SPARC expression can be modulated by FGFR1-III isoform expression. In addition, PDAC cells may inhibit
endogenous SPARC expression in surrounding PSCs by paracrine actions.
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Secreted protein acidic and rich in cysteine (SPARC) or osteo-
nectin is a 32–33kDa calcium-binding glycoprotein shown to
associate with the cell membrane and membrane receptors
(Yan and Sage, 1999). It belongs to a family of matricelluar
proteins and is divided into three modules that exert various
functions (Bradshaw and Sage, 2001). It functions not only to
modulate cell–cell and cell–matrix interactions, but also has
de-adhesive and growth inhibitory properties in non-transformed
cells (Tai and Tang, 2008). In cancer, SPARC may exert divergent
actions reflecting the complexity of this protein (Clark and Sage,
2008; Podhajcer et al, 2008). Thus, in certain types of cancers,
such as melanomas and gliomas, SPARC is associated with a
highly aggressive tumour phenotype, whereas in others, mainly
ovarian, neuroblastomas, and colorectal cancers, SPARC may
function as a tumour suppressor (Tai and Tang, 2008). These
functions are thought to be exerted in part by its ability to
counteract effects of several growth factor families including
fibroblast growth factors (FGFs) (Yan and Sage, 1999; Francki
et al, 2003; Motamed et al, 2003).
Modulation of FGF actions by SPARC is mediated by
FGF receptor (FGFR) 1, because FGFR1 was reported to be
indispensable for SPARC-induced inhibition of FGF signalling
(Motamed et al, 2003). The presence of several FGFR1 isoforms
generated by alternative mRNA splicing makes the analysis of
FGFR1 and SPARC interactions difficult. FGF actions strongly
depend on the presence of specific FGFR isoforms and can be
modulated by changes in isoform expression (Ornitz et al, 1996;
Kornmann et al, 2001; Liu et al, 2007a). Alternative splicing of the
second half of Ig-like domain III generates particular important
isoforms, because this region determines ligand-binding specificity
(Ornitz et al, 1996; Plotnikov et al, 2000). As a consequence, over-
expression of FGFR1-IIIc in pancreatic cancer promoted tumour-
igenesis, whereas over-expression of FGFR1-IIIb inhibited the
malignant phenotype (Kornmann et al, 2002; Liu et al, 2007b). In
addition, several FGFs, signalling through FGFR1-IIIc, are highly
over-expressed in human pancreatic ductal adenocarcinoma
(PDAC) (Yamanaka et al, 1993). Several recent studies reported
increased SPARC levels in human PDAC (Sato et al, 2003;
Guweidhi et al, 2005) associated with poor prognosis (Infante
et al, 2007). SPARC expression was absent in most of the cancer
cells, but instead present at high levels in the peritumoural tissue
harbouring fibroblasts and pancreatic stellate cells (PSCs)
(Guweidhi et al, 2005; Infante et al, 2007).
Despite these recent efforts, the functions of SPARC and its
associations with FGFR1-III isoforms in PDAC remain unclear.
Therefore, the aim of this study was to elucidate SPARC functions
and endogenous SPARC regulation depending on FGFR1-III isoforms
expression in PDAC cells and its interaction with PSC cells.
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sMATERIALS AND METHODS
Cell culture
ASPC-1, BXPC-3, CAPAN-1, MIA PaCa-2, and PANC-1 human
pancreatic cancer cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA), COLO357 and T3M4 human
pancreatic cancer cells were a gift from M Korc (Dartmouth Medical
School, Hanover, NH, USA). Human PSC were isolated and charac-
terised as described earlier (Bachem et al, 2005). PANC-1, Mia PaCa-2,
and COLO357 cells were grown in DME medium and ASPC, BXPC-3,
CAPAN-1, and T3M4 cells in RPMI 1640 medium supplemented with
10% foetal bovine serum (FCS), penicillin G (100unitsml
–1), and
streptomycin (100mgml
–1) termed as complete medium. PSCs
were grown in complete DME/F12 (1:1) medium supplemented
with Amphotericin B (250mgml
–1). The respective media supple-
mented with 0.1% BSA, 5mgl
–1 transferrin, 5mgl
–1 selenium,
penicillin G (100unitsml
–1), and streptomycin (100mgml
–1) were
used as serum-free media. PANC-1 clones PF4 and PF40 (over-
expressing FGFR1-IIIb), and PFc18 and PFc51 (over-expressing
FGFR1-IIIc) were grown in complete DME medium with G418
(1.2mgml
–1). SPARC shRNA-transfected cells were grown in
complete RPMI and DME medium with G418 (0.8 and 1.2mgml
–1,
respectively) for ASPC-1 and PANC-1. Cells were maintained in
monolayer culture at 371C in humidified air with 5% CO2.
Establishment of cell clones over-expressing
FGFR1-III variants
The establishment of the FGFR1-IIIb and -IIIc PANC-1 clones
over-expressing the full-length cDNA of human FGFR1-IIIb or
-IIIc expressed in a modified pSVK3 vector under the control
of the simian virus 40 early promotor in a stable manner was
described earlier (Liu et al, 2007b; Chen et al, 2008).
Establishment of cell clones expressing SPARC shRNA
Validated SureSilencing human SPARC shRNA and control plasmids
were from SuperArray Bioscience Corp. (Frederick, MD, USA).
ASPC-1 and PANC-1 cells were transfected in a stable manner
using lipofectamine (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s protocol. Transfected cells were selected with
G418 (0.8 and 1.2mgml
–1 for ASPC-1 and PANC-1, respectively)
for 14 days before isolation of individual clones.
Immunoblot analysis
Total cell lysates were prepared and followed by immunoblot
analysis as described (Liu et al, 2007b). A rabbit polyclonal
antibody (SPARC, sc-25574, from Santa Cruz) was used (1:200) to
detect SPARC protein. Bound antibodies were visualised using
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Figure 1 SPARC expression and its effects on proliferation, single cell movement, and migration. (A) SPARC protein (upper panel) and mRNA
(lower panel) expression in cultured PDAC cells. Human PSC were used as a positive control. b-actin served as loading control. (B) Cell proliferation.
COLO-357 (’) and PANC-1 (K) cells were cultured in complete medium with increasing concentrations of SPARC. Cell proliferation was determined
after 48h by the MTT assay. The results are shown as mean growth (in %) of untreated control and are means (±s.e.) of quadruplicate determinations from
three separate experiments. *Po0.05. (C) Single cell movement. Movement of single cells was monitored by time-lapse microscopy taking pictures every
10min for 24h. The distance of individual cells (n¼25) was evaluated using the ImageJ 1.32 and Simple Track programme. The results are shown as mean
distances (±s.d.) in mm covered within 24h in the absence ( ) or presence (þ) of SPARC (5mgml
–1). *Po0.05. (D) Migration assay. The number of
cells that moved to the lower side of the Boyden chamber was determined in the absence ( ) or presence (þ) of SPARC (5mgml
–1). The results are
expressed as mean number (±s.d.) of migrated cells within 36h of three separate experiments. *Po0.05.
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senhanced chemiluminescence. To confirm equal loading, mem-
branes were stripped for 30min at 501C in buffer containing
2% SDS, 62.5mM Tris (PH 6.7), and 100mM 2-mercaptoethanol
and reprobed with an anti-b-actin antibody to show equal loading.
RT–PCR
Total RNA (1–2mg) was reverse transcribed using a SuperScript
pre-amplification kit (Invitrogen). Primers were based on the
sequences reported on Genebank (NM 003118). SPARC sense
sequence was 50-GTGGGCAAAGGGAAGTAACA-30 and SPARC
anti-sense sequence 50-GGGAGGGTGAAGAAAAGGAG-30. The
expected product size of SPARC cDNA was 514bp. PCR
amplification was performed in 25ml reaction volumes containing
0.2mM dNTPs, 20pmol of each oligonucleotide primer, and 0.2U
Tag polymerase in PCR buffer. cDNA was amplified on a PCR
thermal controller with an initial denaturation at 951C for 5min,
followed by cycles of 951C for 1min, 651C for 1min, and 721C for
1min, 27 cycles, and a final extension step of 721C for 10min. The
amount of starting cDNA was adjusted using b-actin intensity.
Anchorage-dependent growth and functional assays
The effects of exogenous SPARC (from murine parietal yolk
sac cells, S5174 Sigma, St Louis, MO, USA) on proliferation were
determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay. The indicated amount of cells was
seeded in 96-well plates and propagated for 24h in complete
medium before further analysis. To assess basal growth and the
effect of SPARC alone, 5000 cells per well were incubated for 48h
in complete medium in the absence or presence of SPARC. To
assess the effects of SPARC on FGF-induced proliferation, cells
(10000 per well) were propagated for 48h in serum-free medium
including the indicated factors. FGF1 (recombinant human FGF
acidic, R&D Systems) and FGF2 (recombinant human FGF basic,
R&D Systems) were added in the presence of heparin (1mgml
–1).
To analyse N-linked protein, glycosylation cells were incubated
in the absence or presence of tunicamycin (5mgml
–1, T7765
Sigma) for 24h as described (Liu et al, 2007a). To assess the effect
of kinase, inhibitors cells were incubated in the absence or
presence of the p38-mitogen-activated protein kinase (MAPK)
inhibitor SB203580 (Calbiochem, Darmstadt, Germany) and the c-
Jun N-terminal kinase (JNK) inhibitor SP600125 (Calbiochem) for
24h (Liu et al, 2007a).
Single cell movement
Cells (50000 per well) were seeded onto fibronetin-coated (5mgml
–1
in PBS) six-well plates and grown for 20h. Cells were then incubated in
the presence or absence of SPARC (5mgml
–1) for 24h. Cell movement
during that period was monitored by an Olympus IX81 motorised
inverted microscope taking pictures every 10min (Liu et al, 2007b).
The total distance of individual cells covered within 24h was deter-
mined using the ImageJ 1.32 program (NIH, Bethesda, MD, USA).
Cell migration assay
The ability of cells to migrate through filters was measured using a
BioCoat Matrigel invasion chamber (BD Biosciences, San Jose, CA,
USA). Cell culture inserts with an 8mm pore size PET membrane
were used according to the protocol of the manufacturer. The bottom
chamber included medium (0.75ml) containing 10% FCS, whereas
cells (1.0 10
5 suspended in 0.5ml of medium containing 1% FCS)
were seeded into the upper chamber and incubated overnight at 371C
in a humidified atmosphere containing 5% CO2. Cells were then
incubated in the absence or presence of exogenous SPARC (5mgml
–1)
for another 24h. Remaining cells on the upper surface were
mechanically removed. Membranes were then washed, fixed, and
stained by Diff-Quik (Medion Diagnostics, Du ¨dingen, Switzerland).
The number of cells that migrated to the lower surface of the filters
was determined by counting stained cells under a light microscope.
Anchorage-independent growth assay
Basal anchorage-independent cell growth was assessed by a
double-layer soft-agar assay as described (Kornmann et al,
2002). Briefly, cells were suspended in complete medium contain-
ing 0.3% agar and seeded in triplicate in six-well plates onto a base
layer of complete medium containing 0.5% agar. One mililiter of
complete medium containing 0.3% agar was added every 5 days.
After 14 days, 300mg MTT per well was added to stain vital
colonies for 24h before counting by microscopy.
In vivo tumourigenicity assay
To assess the effect of expression of SPARC on xenograft formation,
10
6 cells per site were injected s.c. into two sites of 4- to 6-week-old
female athymic (nude) mice. Animals were monitored for tumour
formation every 4 days. Tumour size was measured in three
dimensions. Tumour volume was determined by the equation
vol¼l w d 0.5, where l is the length, w is the width, and d is
the diameter. Animals had to be killed 12 weeks after injection
according to our animal protocol (#718) if neither tumour volume
(42cm
3) nor skin ulcerations prompted earlier termination.
Immunohistochemistry of xenograft tumours
SPARC expression in control-transfected (n¼10) and FGFR1-IIIb
over-expressing (n¼10) xenograft tumours (Liu et al, 2007b)
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Figure 2 SPARC shRNA expression and its effect on basal cell growth.
(A) SPARC protein (upper panel) and mRNA (lower panel) expression
in wild-type ASPC-1 and PANC-1 cells, vector alone (control)-transfected
clones (AN-9, PN-21), and SPARC shRNA-expressing clones (A2-7, A3-3,
P1-15, P1-20), respectively. b-actin served as loading control. The long
exposure autoradiographs for the SPARC immunoblot analysis revealed
that still faint bands of SPARC are detectable in shRNA-expressing clones.
(B) Basal cell proliferation. Basal growth was determined after 48h in
complete medium by the MTT assay. The results are shown as mean
growth (in %) of the respective wild-type cell lines and are means (±s.e.)
of quadruplicate determinations from six separate experiments. *Po0.05
compared with wild-type and control-transfected cells.
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swas determined by immunohistochemical analysis. SPARC
immunohistochemistry was performed using formalin-fixed and
paraffin-embedded sections using a rabbit polyclonal antibody
detecting human SPARC (1:2000, sc-25574 from Santa Cruz) in
combination with a secondary biotynylated goat anti-rabbit
antibody and a Vectastain Elite ABC kit (Vector Lab, Burlingame,
CA, USA) according to the protocol of the manufacturer.
Detection of SPARC in conditioned medium
Indicated cells were grown in complete medium to 70% confluency
in 10cm dishes. After washing twice with PBS, cells were incubated
for 48h in 10ml of serum-free medium containing proteinase
inhibitors as described (Kornmann et al, 1997). For immunoblot
analysis, conditioned medium of five dishes was collected and
incubated at 41C overnight after adjusting the pH to 7.4 and
adding 50ml slurry heparin sepharose (CL-6B, Pharmacia Bio-
tech, Piscataway, NY, USA) to pull-down calcium-binding
proteins (Kornmann et al, 1997). The beads were collected by
centrifugation, washed three times with 0.45 M NaCl/20mM Tris–
HCl (pH 7.4), and resuspended in 2  Laemmli buffer. Samples
were boiled for 5min and subjected to immunoblot analysis.
Statistics
The results were expressed as mean expression levels (±s.d. or s.e.m.).
Student’s t-test or rank sum test was used for statistical analysis.
A P-value o0.05 was taken as level of significance (two sided).
RESULTS
Expression of SPARC and its effects on proliferation and
migration in cultured PDAC cells
A clear signal of SPARC protein, migrating under reducing
conditions at 43kDa, and mRNA was found in ASPC-1 and
PANC-1 cells (Figure 1A), whereas very week signals of SPARC
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Figure 3 Inhibition of endogenous SPARC and its effect on cell migration, colony-formation, xenograft growth, and FGF-induced proliferation.
(A) Migration assay. The number of cells that moved to the lower side of the Boyden chamber was determined as described in the legend of Figure 1 for
wild-type ASPC-1 and PANC-1 cells, vector alone (control)-transfected clones (AN-9, PN-21), and SPARC shRNA-expressing clones (A2-7, A3-3, P1-15,
P1-20), respectively. The results are expressed as mean number (±s.d.) of migrated cells within 36h of three separate experiments. *Po0.05 compared
with wild-type and control-transfected cells. (B) Soft-agar assay. Colony-formation of indicated cells was determined after 14 days by staining and counting
viable colonies. The results are mean number of colonies per dish (±s.e.) of triplicate determinations from five separate experiments. *Po0.05 compared
with wild-type and control-transfected cells. (C) Xenograft formation. Indicated PANC-1 cells (10
6 per site) were subcutaneously injected into nude mice.
Tumour growth was followed for 80 days. Eleven sites of 16 injected sites of PN-21 and 6 of 8 of PN-22 control-transfected clones and 12 of 16 of P1-20
and 8 of 8 of P1-15 SPARC shRNA-expressing clones developed tumours. Shown is the mean tumour volume for developed nodules: PN-21 (n¼11),
PN-22 (n¼6), P1-15 (n¼8), P1-20 (n¼12). *Po0.05 compared with PN-21. (D) FGF-induced proliferation. Wild-type PANC-1, control-transfected
(PN-21), and SPARC shRNA (P1-15, P1-20)-expressing cells were cultured for 48h in serum-free medium in the presence of heparin alone (1mgml
–1),
5n M FGF1 or FGF2 in the presence of heparin, or 5nM EGF. Proliferation was determined by the MTT assay. The results are shown as mean growth (in %)
of respective untreated control and are means (±s.e.) of quadruplicate determinations from three separate experiments. *Po0.05 compared with the
effects of ligand in wild-type and control-transfected cells.
Inhibition of SPARC expression
G Chen et al
191
British Journal of Cancer (2010) 102(1), 188–195 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
smRNA were observed in the remaining five cell lines (Figure 1A,
lower panel). In contrast, higher levels of SPARC were found in
human PSCs (Figure 1A). Independent of endogenous SPARC
expression, exogenous SPARC inhibited proliferation of PDAC
cells. This effect was most pronounced in COLO-357 and PANC-1
cells (Figure 1B). Exogenous SPARC (5mgml
–1) also reduced
proliferation of CAPAN-1 ( 21±0.1% s.e.m.) and MIA PaCa-2
cells ( 20±1.8% s.e.m.), but was without marked effect in ASPC-1
( 12±0.4% s.e.m.), BxPC-3 ( 7.5±1.1% s.e.m.), and T3M4 cells
(0.7±2.1% s.e.m.).
The effects of exogenous SPARC (5mgml
–1) on single cell
movement and migration were investigated in PANC-1 and MIA
PaCa-2 cells. SPARC reduced the distance covered within 24h by
38% and 28% in PANC-1 and MIA PaCa-2 cells, respectively
(Figure 1C). Cell migration was inhibited in the presence of SPARC
by 58% and 26%, respectively (Figure 1D).
Inhibition of endogenous SPARC expression
To determine the importance of endogenous SPARC expression for
the malignant phenotype of cultured PDAC cells, ASPC-1 and
PANC-1 cell clones were established expressing SPARC shRNA in a
stable manner. Screening of the clones was performed by
immunoblot analysis. The 43kDa band corresponding to SPARC
protein was almost completely inhibited in SPARC shRNA-
expressing clones in comparison with wild-type and control-
transfected clones. The SPARC protein band was only detectable
on long exposures in SPARC shRNA-expressing clones
(Figure 2A). Two-week additional bands above the SPARC band
and an intensive band of about 20kDa were picked up on the long
exposure autoradiographs by the antibody in all lysates
(Figure 2A). Their level was not altered. A total of 16
shRNA-expressing clones (8 ASPC, 8 PANC-1) were randomly
picked and screened for basal cell growth. Inhibition of endogenous
SPARC resulted in enhanced basal cell growth in all but one (P4-20,
101±2% s.e.) clone. The basal growth of ASPC-1 clones A1-6,
A1-12, A3-4, A3-13, A4-10, and A4-11 was 130% (±4% s.e.), 119%
(±5% s.e.), 137% (±5% s.e.), 130% (±5% s.e.), 139% (±6% s.e.),
and 132% (±5% s.e.), respectively, and for PANC-1 clones P3-20,
P1-21, P2-9, P3-21, and P4-21 122% (±6% s.e.), 123% (±6% s.e.),
122% (±5% s.e.), 116% (±5% s.e.), and 136% (±2% s.e.),
respectively, compared with respective wild-type cells (four
separate experiments). The results of control-transfected clones
AN-9 and PN-21 as well as of SPARC shRNA-expressing clones
A2-7, A3-3, P1-15, and P1-20 are displayed in Figure 2B. Addition
of exogenous SPARC (5mgml
–1) to SPARC-deprived cell clones
inhibited their basal growth to the same extent as seen in wild-type
cells by 29.5% (±5.2% s.e.m.) and 13.9% (±1.1% s.e.m.) in
PANC-1 (P1-15) and ASPC-1 (A2-7) clones, respectively.
SPARC shRNA expression enhanced the malignant phenotype of
PDAC cells. Inhibition of SPARC resulted in enhanced basal cell
migration (Figure 3A), basal colony formation in soft-agar
(Figure 3B), and xenograft formation (Figure 3C). Moreover,
inhibition of endogenous SPARC expression was accompanied by
enhanced proliferative activity of FGF1 and FGF2, but not EGF
(Figure 3D).
Effects of FGFR1 expression on SPARC modulation of
FGF1 and FGF2
Modulation of FGF actions by SPARC was reported to depend on
FGFR1 expression (Motamed et al, 2003). It is not known, whether
there are differences among the existing FGFR1 variants in
mediating SPARC-modulated FGF actions. Therefore, we next
investigated SPARC modulation of FGF-depended proliferation in
regard to FGFR1-III isoform expression. Wild-type PANC-1,
control-transfected (PN5), FGFR1-IIIb over-expressing (PF4),
and FGFR1-IIIc over-expressing (PFc51) cells were incubated with
FGF1 and FGF2 in the presence and absence of SPARC. As
reported earlier, over-expression of FGFR1-IIIc (PFc51) resulted in
enhanced FGF1- and FGF2-induced proliferation in comparison
with wild-type, control-transfected, and FGFR1-IIIb (PF4) over-
expressing cells (Figure 4). FGF2 effects were not markedly altered
by exogenous SPARC. Irrespective of the FGFR1-III isoform and
the degree of FGF1-induced proliferation, the inhibitory effects of
SPARC on FGF1-induced proliferation seemed to be slightly more
pronounced in FGFR1-III over-expressing clones compared with
cells expressing lower levels of FGFR1 (Figure 4). This observation
did not reach any significance.
Effect of FGFR1-III domain expression on SPARC
expression
Over-expression of FGFR1-IIIb inhibited and FGFR1-IIIc enhanced
the malignant phenotype of PDAC cells (Liu et al, 2007b). In the
next step, endogenous SPARC expression in PANC-1 cells over-
expressing either FGFR1-IIIb (PF4, PF40) or FGFR1-IIIc (PF18c,
PF51c) was characterised. Expression of SPARC was enhanced in
FGFR1-IIIb over-expressing clones, whereas SPARC expression
was decreased in FGFR1-IIIc over-expressing clones (Figure 5A).
This was confirmed in a xenograft model in vivo. Immuno-
histochemical analysis of SPARC protein expression of tumours
over-expressing FGFR1-IIIb (Liu et al, 2007b) revealed that SPARC
protein was up-regulated in FGFR1-IIIb over-expressing tumours
(Figure 5B).
Incubation with tunicamycin, an inhibitor of glycosylation,
showed that up-regulated SPARC protein in FGFR1-IIIb over-
expressing PANC-1 cells was a glycosylated protein similar to wild-
type cells (Figure 5C).
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Figure 4 Modulation of FGF1- and 2-induced proliferation by exogenous
SPARC in cells over-expressing FGFR1-III isoforms. Wild-type (PANC-1),
control-transfected (PN5), FGFR1-IIIb over-expressing (PF4), and FGFR1-IIIc
over-expressing (PFc51) cells were incubated for 48h in serum-free medium
with 5nM FGF1 or FGF2 alone and in the presence of SPARC (5mgml
–1).
The results are shown as mean growth (in %) of control (heparin only)
and are means (±s.e.) of quadruplicate determinations from three separate
experiments. *Po0.05 compared with ligand alone.
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ing clones is unclear. We showed recently that FGFR1-IIIb over-
expression was accompanied by up-regulation of p38-MAPK and
JNK activities (Liu et al, 2007a,b). Incubating FGFR1-IIIb over-
expressing PF4 and PF40 cells with increasing concentrations of
the p38-MAPK inhibitor SB203580 (10, 20, and 40mM) and the JNK
inhibitor SP600125 (1, 2, and 4mM) revealed that SB203580 reduced
expression of SPARC, whereas SP600125 was without effect. In
Figure 5D, the effects of 20mM SB203580 and of 2mM SP600125 are
shown for FGFR1-IIIb over-expressing clones and wild-type
PANC-1 cells. Densitometric analysis in relation to b-actin of
three separate experiments revealed that SB203580 reduced SPARC
expression in wild-type PANC-1, PF4, and PF40 cells by 65%
(±8% s.d.), 47% (±5% s.d.), and 62% (±9% s.d.), respectively.
SP600125 was without significant effect.
Interactions of PDAC cells and stromal cells
Human PSCs expressed high levels of SPARC (Figure 1A). SPARC
was also detectable in the pull down of heparin-binding proteins of
conditioned medium of PSCs, but not of COLO-357 and PANC-1
pancreatic cancer cells (Figure 6A). To investigate whether SPARC
expression can be altered by paracrine mechanisms, PSCs were
incubated with conditioned medium harvested from PSCs and
pancreatic cancer cells (Figure 6B). Endogenous SPARC expression
in PSCs was reduced by conditioned medium of COLO-357 and
PANC-1 cells added to PSCs for 48h, but not by conditioned
medium of PSCs (Figure 6B). Conditioned medium of PSCs did not
alter SPARC expression in PANC-1 and ASPC-1 cells (data not
shown).
DISCUSSION
SPARC is a matricellular protein with antiproliferative and
counteradhesive functions (Yan and Sage, 1999). Its function
in cancer is discussed in a very controversial manner (Clark
and Sage, 2008; Podhajcer et al, 2008; Tai and Tang, 2008).
In certain types of cancers, such as melanomas and gliomas,
SPARC is associated with a highly aggressive tumour pheno-
type. In others, mainly ovarian, neuroblastomas, and colorectal
cancers, SPARC may function as a tumour suppressor (Tai and
Tang, 2008). We showed in this study that exogenous SPARC
can inhibit cell proliferation, single cell movement, and migra-
tion of cultured PDAC cells. These exogenous SPARC functions
were independent of endogenous SPARC expression. As reported
(Sato et al, 2003; Guweidhi et al, 2005), the majority of the
cell lines did not express endogenous SPARC, probably as a
result of aberrant hypermethylation (Sato et al, 2003; Cheetham
et al, 2008).
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Figure 5 Function of FGFR1-III isoform expression and p38-MAPK activity for SPARC expression. (A) SPARC expression in cells over-expressing
FGFR1-IIIb and FGFR1-IIIc. The upper panels show representative SPARC immunoblot and PCR analyses in wild-type PANC-1 cells, PN5 and PN6 control-
transfected, FGFR1-IIIb over-expressing PF4 and PF40, and FGFR1-IIIc over-expressing PFc18 and PFc51 cells. Densitometry of bands in relation to
respective b-actin of three separate experiments is shown in the lower panel. The results are mean expression levels (±s.d.) in relation to wild-type
PANC-1 (100%) of three separate experiments. *Po0.05 compared with wild-type and control-transfected cells. (B) SPARC expression in xenograft
tumours. Immunohistochemical analysis of SPARC was performed in FGFR1-IIIb over-expressing (upper panel) and control-transfected (lower panel)
tumours (Liu et al, 2007b). Representative areas from proliferating areas are shown. The arrow depicts the area of magnification of the inset. Bar¼50mm.
(C) Glycosylation of SPARC. Incubation of FGFR1-IIIb over-expressing PF4 and wild-type PANC-1 cells with tunicamycin showed that SPARC protein
was glycosylated. (D) Effects of the p38-MAPK inhibitor SB203580 and the JNK inhibitor SP600125 on endogenous SPARC expression in FGFR1-IIIb
over-expressing PF4 and PF40 and wild-type PANC-1 cells. Indicated cells were incubated in the absence ( ) and presence (þ) of SB203580 (20mM)
or SP600125 (2mM) for 24h before analysis.
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by small hairpin RNA enhanced cell proliferation, migration,
colony formation, and xenograft formation. These results indicate
that endogenous SPARC may act as a tumour suppressor in PDAC
cells, a function SPARC also has in ovarian, neuroblastomas, and
colorectal cancers (Tai and Tang, 2008). This function of a tumour
suppressor is also supported by our finding that inhibition of
endogenous SPARC resulted in a doubling of the mitogenic activity
of FGF1 and FGF2, two ligands of the FGF family known to be
over-expressed in the majority of pancreatic cancers and to
correlate with poor prognosis (Yamanaka et al, 1993).
The presence of FGFR1 is important for mediating SPARC
functions in endothelial cells and skeletal myoblasts (Motamed
et al, 2003). All cell lines used in our study expressed various levels
of FGFR1 (Kornmann et al, 2002). Inhibition of FGF1-induced
proliferation by exogenous SPARC was enhanced in FGFR1-III
over-expressing cells compared with controls. This effect was
independent of the FGFR1-III isoform. Thus, exogenous SPARC
actions depend on the FGFR1 levels, but are independent of the
domain III isoform expression.
Down-regulation of SPARC in pancreatic cancer cells is believed
to depend on DNA methylation (Sato et al, 2003; Guweidhi et al,
2005; Infante et al, 2007; Cheetham et al, 2008). Another reason
contributing to the down-regulation of SPARC in human
pancreatic cancer cells may be the over-expression of FGFR1-IIIc.
FGFR1-IIIc is the predominant FGFR1 isoform expressed in PDAC
(Kornmann et al, 2002). FGFR1-IIIb usually expressed in cells of
epithelial origin is almost absent in PDAC (Kornmann et al, 2002).
Re- or over-expression of FGFR1-IIIb in PDAC cells resulted in a
marked up-regulation of endogenous SPARC in vitro and in vivo.
In contrast, an additional over-expression of FGFR1-IIIc further
lowered endogenous SPARC expression. We recently showed that
over-expression of FGFR1-IIIb in PDAC cells reverted the
malignant phenotype inhibiting proliferation, single cell move-
ment, and migration in vitro, as well as xenograft formation and
growth in vivo (Liu et al, 2007b). On the other hand, it is well
known that over-expression of FGFR1-IIIc enhances the malignant
phenotype of PDAC (Wagner et al, 1998; Kornmann et al, 2002).
FGFR1-IIIb over-expression in PDAC cells resulted in strong
p38-MAPK and JNK activitation (Liu et al, 2007a,b). In this study,
we also investigated the effects of specific inhibitors of these
kinases on endogenous SPARC levels. Our results showed that
endogenous SPARC levels could be down-regulated by inhibition
of p38-MAPK, but not of JNK. Therefore, our observations suggest
that modulation of endogenous SPARC expression may be one of
the mechanisms resulting in the different phenotypes seen for the
FGFR1-III domain variants and that the observed FGFR1-IIIb-
induced induction of endogenous SPARC is mediated through
p38-MAPK.
Recent studies investigating SPARC expression in human
pancreatic tissues reported high levels of SPARC in the surround-
ing stromal tissue harbouring fibroblasts and PSCs, whereas
SPARC was often absent in the cancer cells (Guweidhi et al, 2005;
Infante et al, 2007). High SPARC expression in the stroma
portended a poor patient prognosis (Infante et al, 2007). We
showed in our study that PSCs express higher levels of endogenous
SPARC than cultured PDAC cells and that SPARC is detectable in
the conditioned medium of PSCs. Our study also revealed that
conditioned medium of pancreatic cancer cells down-regulated
endogenous SPARC expression of PSCs. In contrast, co-culture of
fibroblasts in the presence of PDAC cells augmented SPARC
expression in fibroblasts (Sato et al, 2003), suggesting that high
SPARC expression in the tumour stroma may be mainly a result of
augmented SPARC expression in stromal fibroblasts.
In summary, we showed that inhibition of endogenous SPARC
enhances the malignant phenotype of PDAC cells and showed that
endogenous SPARC expression is regulated by FGFR1 domain III
isoform expression. On the basis of these observations, we
conclude that endogenous SPARC levels can contribute to the
reversion of the malignant phenotype and may, therefore, act as a
tumour suppressor in human PDAC cells. Future studies in human
pancreatic cancer could aim at the design of treatment strategies
specifically targeting SPARC–FGFR1 interactions.
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